DOI work
Fetched
Post
crossref
Patricia Cogram, Daniel L. Alkon, David Crockford, Robert M. J. Deacon, Michael J. Hurley, Francisco Altimiras, Miao-Kun Sun, Michael Tranfaglia
(2020).
Chronic bryostatin-1 rescues autistic and cognitive phenotypes in the fragile X mice.
Scientific Reports, 10(1), 18058.
Springer Science and Business Media LLC.
- Publication date
-
22 Oct 2020
- Identifier
-
10.1038/s41598-020-74848-6
- Authors
-
Patricia Cogram,
Daniel L. Alkon,
David Crockford,
Robert M. J. Deacon,
Michael J. Hurley,
Francisco Altimiras,
Miao-Kun Sun,
Michael Tranfaglia
- Source
- Scientific Reports
- Details
- 10(1), 18058
- Reference type
- article
- Publisher
- Springer Science and Business Media LLC
- Metadata source
- crossref
Abstract
Abstract Fragile X syndrome (FXS), an X-chromosome linked intellectual disability, is the leading monogenetic cause of autism spectrum disorder (ASD), a neurodevelopmental condition that currently has no specific drug treatment. Building upon the demonstrated therapeutic effects on spatial memory of bryostatin-1, a relatively specific activator of protein kinase C (PKC)ε, (also of PKCα) on impaired synaptic plasticity/maturation and spatial learning and memory in FXS mice, we investigated whether bryostatin-1 might affect the autistic phenotypes and other behaviors, including open field activity, activities of daily living (nesting and marble burying), at the effective therapeutic dose for spatial memory deficits. Further evaluation included other non-spatial learning and memory tasks. Interestingly, a short period of treatment (5 weeks) only produced very limited or no therapeutic effects on the autistic and cognitive phenotypes in the Fmr1 KO2 mice, while a longer treatment (13 weeks) with the same dose of bryostatin-1 effectively rescued the autistic and non-spatial learning deficit cognitive phenotypes. It is possible that longer-term treatment would result in further improvement in these fragile X phenotypes. This effect is clearly different from other treatment strategies tested to date, in that the drug shows little acute effect, but strong long-term effects. It also shows no evidence of tolerance, which has been a problem with other drug classes (mGluR5 antagonists, GABA-A and -B agonists). The results strongly suggest that, at appropriate dosing and therapeutic period, chronic bryostatin-1 may have great therapeutic value for both ASD and FXS.
Study authors in this cited reference